Novel gene nedl-1

• US 20050064411A1
• Filed: 08/23/2002
• Published: 03/24/2005
• Est. Priority Date: 08/24/2001
• Status: Abandoned Application

• Current Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated
• Original Assignee: Chiba-Prefecture, Hisamitsu Pharmaceutical Company Incorporated
• Inventors: Nakagawara, Akira, Miyazaki, Kou
• Application Number:
  US10/487,132
• Publication Number:
  US 20050064411A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12N 9/93 Ligases (6)
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

Diagnostic agent or kit for the prognosis of neuroblastoma containing a nucleic acid probe or primer utilizing the nucleic acids derived from the NEDL-1 gene or the NEDL-1 protein, as well as method for diagnosing the prognosis of neuroblastoma.

Claims

1. A nucleic acid probe comprising nucleic acid (a) or nucleic acid (b):

(a) a nucleic acid having a portion of a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing or a base sequence complementary thereto; and

(b) a nucleic acid capable of hybridizing to the nucleic acid comprising a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing, or having a base sequence complementary to said base sequence.

2. The nucleic acid probe according to claim 1, wherein the nucleic acid is DNA.

3. The nucleic acid probe according to claim 1 or 2, wherein the nucleic acid has a base length of at least 20 bases.

4. The nucleic acid probe according to claim 3, wherein the base sequence set forth in SEQ ID NO:

2 is a full-length thereof.

5. A diagnostic agent for the prognosis of neuroblastoma, the agent comprising the nucleic acid probe according to any of claims 1-4, as the effective ingredient.

6. A primer containing DNA (a) or DNA (b):

(a) DNA having a portion of a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing or a base sequence complementary thereto;

or

(b) DNA capable of hybridizing to the DNA comprising a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing, or having a base sequence complementary to said base sequence.

7. A kit for diagnosing the prognosis of neuroblastoma, the kit comprising the primer according to claim 6 as the effective ingredient.

8. A method for diagnosing the prognosis of neuroblastoma, the method comprising detecting the presence or absence of a nucleic acid comprising a base sequence set forth in SEQ ID NO:

2 in the Sequence Listing in a clinical tissue sample of neuroblastoma.

9. A method for diagnosing the prognosis of neuroblastoma, the method comprising detecting the presence or absence of a protein comprising an amino acid sequence set forth in SEQ ID NO:

1 in the Sequence Listing in a clinical tissue sample of neuroblastoma.

10. A method for diagnosing the prognosis of neuroblastoma, the method comprising contacting with a clinical tissue sample of neuroblastoma, (a) a nucleic acid having a portion of a base sequence set forth in SEQ ID NO:

2 in the Sequence Listing or a base sequence complementary thereto or (b) a nucleic acid capable of hybridizing to the nucleic acid comprising a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing, or having a base sequence complementary to said base sequence; and

analyzing the expression of a protein comprising an amino acid sequence set forth in SEQ ID NO;

1 in the Sequence Listing or an level thereof.

11. A polyubiqutination agent comprising as the effective ingredient, a protein comprising a base sequence set forth in SEQ ID NO:

1 in the Sequence Listing.

12. The polyubiqutination agent according to claim 11, wherein the substrate to be ubiquitinated is β

-amyloid precursor protein (β

APP).

13. The polyubiqutination agent according to claim 11, wherein the substrate to be ubiquitinated is β

-amyloid precursor protein intracellular region (AICD)

14. The polyubiqutination agent according to claim 11, wherein the substrate to be ubiquitinated is a superoxide dismutase mutant (SOD1).

15. A composition for modulating β

-amyloid precursor protein (APP), the composition comprising an effective amount of a protein comprising an amino acid sequence set forth in SEQ ID NO;

1 in the Sequence Listing to modulate the expression, the production or the formation of β

-amyloid precursor protein in a cell.

16. A composition for modulating β

-amyloid precursor protein (β

APP), the composition comprising an effective amount of a nucleic acid comprising a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing to modulate the expression, the production or the formation of β

-amyloid precursor protein in a cell.

17. A method for modulating the expression, the production or the formation of β

-amyloid precursor protein in a cell, the method comprising administering an effective amount of a protein comprising an amino acid sequence set forth in SEQ ID NO;

1 in the Sequence Listing to modulate the expression, the production or the formation of β

-amyloid precursor protein in a cell.

18. A method for modulating the expression, the production or the formation of β

-amyloid precursor protein in a cell, the method comprising administering an effective amount of a nucleic acid comprising a base sequence set forth in SEQ ID NO;

2 in the Sequence Listing to modulate the expression, the production or the formation of β

-amyloid precursor protein in a cell.

19. A composition for modulating superoxide dismutase (SOD1) activity, the composition comprising an effective amount of a protein comprising an amino acid sequence set forth in SEQ ID NO:

1 in the Sequence Listing to modulate the superoxide dismutase (SOD1) activity in a cell.

21. The composition for modulating superoxide dismutase (SOD1) activity according to claim 19 or 20, wherein the superoxide dismutase (SOD1) is a mutant type.

20. A composition for modulating superoxide dismutase (SOD1) activity, the composition comprising an effective amount of a nucleic acid comprising a base sequence set forth in SEQ ID NO:

1 in the Sequence Listing to modulate the superoxide dismutase (SOD1) activity in a cell.

22. A method for modulating superoxide dismutase activity in a cell, the method comprising administering to the cell, an effective amount of a protein comprising an amino acid sequence set forth in SEQ ID NO:

1 in the Sequence Listing to modulate the superoxide dismutase (SOD1) activity.

24. The method according to claim 22 or 23, wherein the superoxide dismutase (SOD1) is a mutant type.

23. A method for modulating superoxide dismutase (SOD1) activity in a cell, the method comprising administering to the cell, an effective amount of a nucleic acid comprising a base sequence set forth in SEQ ID NO:

2 in the Sequence Listing to modulate the superoxide dismutase (SOD1) activity.